공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

당단백질 41(gp41) : 파이프라인 리뷰

Glycoprotein 41 (gp41) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 363121
페이지 정보 영문 67 Pages
가격
US $ 3,500 ₩ 4,143,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,286,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,429,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


당단백질 41(gp41) : 파이프라인 리뷰 Glycoprotein 41 (gp41) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 67 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

당단백질 41(gp41) 개발 상황에 대해 조사분석했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 정리하여 전해드립니다.

목차

서론

개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 분야별
  • 개발중인 제품 : 적응별
  • 개발중인 제품 : 기업별
  • 개발중인 제품 : 대학/연구기관별

치료제 평가

  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Amunix Operating Inc
  • Frontier Biotechnologies Inc
  • InnaVirVax SA
  • Longevity Biotech Inc
  • Mymetics Corp
  • Navigen Inc
  • Osel Inc
  • Pharis Biotec GmbH

약제 개요

휴지 상태 프로젝트

개발이 중지된 프로젝트

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

KSA 17.11.02

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Frontier Biotechnologies Inc, 2021
  • Pipeline by Longevity Biotech Inc, 2021
  • Pipeline by Minka Therapeutics SA, 2021
  • Pipeline by Molecular Express Inc, 2021
  • Pipeline by Mymetics Corp, 2021
  • Pipeline by Navigen Inc, 2021
  • Pipeline by Novodux, 2021
  • Pipeline by Osel Inc, 2021
  • Pipeline by Protheragen Inc, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

According to the recently published report 'Glycoprotein 41 - Drugs In Development, 2021'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 18 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.

The report 'Glycoprotein 41 - Drugs In Development, 2021' outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 5 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
  • The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Glycoprotein 41 (gp41) - Overview
  • Glycoprotein 41 (gp41) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Glycoprotein 41 (gp41) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
  • Frontier Biotechnologies Inc
  • Longevity Biotech Inc
  • Minka Therapeutics SA
  • Molecular Express Inc
  • Mymetics Corp
  • Navigen Inc
  • Novodux
  • Osel Inc
  • Protheragen Inc
  • Glycoprotein 41 (gp41) - Drug Profiles
  • albuvirtide LA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CPT-31 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DS-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HIV-1 vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • human immunodeficiency virus (virus like particles) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LBT-5001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Inhibit GP41 for HIV Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibody to Target GP41 for HIV Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MPER-656 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MYMV-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VAC-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VAC-3S - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Glycoprotein 41 (gp41) - Dormant Products
  • Glycoprotein 41 (gp41) - Discontinued Products
  • Glycoprotein 41 (gp41) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 19, 2021: Frontier biotechnologies first long-acting injectable (Aikening), in a two drug regimen for HIV, proves safe and efficacious for patients
  • Dec 10, 2019: Navigen announces FDA clearance of its IND application to initiate first-in-human studies for CPT31, a novel, D-peptide HIV entry inhibitor
  • Apr 29, 2019: Mymetics receives funding from NIH for Novel HIV Vaccine Study
  • Aug 21, 2018: Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA
  • Jun 07, 2018: Frontier Biotech receives marketing authorization from China FDA for Aikening (albuvirtide for injection), China's first new drug for the treatment of HIV
  • Sep 18, 2017: Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31
  • Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
  • Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science
  • Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen's HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
  • Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
  • Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate
  • Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial
  • May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US
  • Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed
  • Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q